Pharmaxis Ltd (PXS)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013567
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lung function and relieves the mucus burden in the lungs of patients. Its products pipeline includes orbital dry powder inhaler, PXS-4728A, LOXL-2 and ASM8. The company offers solutions for cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease, and inflammatory and fibrotic diseases such as nonalcoholic steatohepatitis and pulmonary fibrosis, among others. Pharmaxis is headquartered in Sydney, New South Wales, Australia.

Pharmaxis Ltd (PXS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Pharmaxis Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 11
Pharmaxis Enters into Partnership with Synairgen 12
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 13
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 14
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 15
Equity Offering 16
Pharmaxis Announces Second Tranche Of Private Placement Of Shares For US$20 Million 16
Pharmaxis Completes Second Tranche Of Private Placement Of Common Stock For US$7 Million 17
Pharmaxis Completes Second Tranche Of Rights Issue Of Common Stock For US$16.6 Million 19
Asset Transactions 21
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 21
Pharmaxis Ltd – Key Competitors 23
Pharmaxis Ltd – Key Employees 24
Pharmaxis Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 26
Corporate Communications 27
Oct 19, 2017: Pharmaxis Strengthens Drug Discovery Capability as its Technology Platform Continues to Deliver 27
Product News 28
Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 28
Product Approvals 29
Sep 27, 2016: Pharmaxis Announces Russian Approval for Bronchitol Largest Market Accessed to Date 29
Clinical Trials 30
Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials 30
Jul 15, 2016: Pharmaxis Completes Recruitment of Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market 31
Mar 22, 2016: Synairgen Announces Positive LOXL2 results 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pharmaxis Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Pharmaxis Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 11
Pharmaxis Enters into Partnership with Synairgen 12
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 13
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 14
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 15
Pharmaxis Announces Second Tranche Of Private Placement Of Shares For US$20 Million 16
Pharmaxis Completes Second Tranche Of Private Placement Of Common Stock For US$7 Million 17
Pharmaxis Completes Second Tranche Of Rights Issue Of Common Stock For US$16.6 Million 19
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 21
Pharmaxis Ltd, Key Competitors 23
Pharmaxis Ltd, Key Employees 24
Pharmaxis Ltd, Subsidiaries 25

★海外企業調査レポート[Pharmaxis Ltd (PXS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eneco Holding NV-エネルギー分野:企業M&A・提携分析
    Summary Eneco Holding N.V. (Eneco) is an integrated energy company. It produces, trades, transmits and supplies gas, electricity and heat. Eneco undertakes the sale, rental, installation, and maintenance of heating and hot water equipment; and maintenance of the electricity, gas and district heat ne …
  • Alstom SA (ALO)-エネルギー分野:企業M&A・提携分析
    Summary Alstom SA (Alstom) is a manufacturer of transportation vehicles. It designs, develops and manufactures rail transport equipment, systems, services and signaling for urban, suburban, regional and main line passenger transportation, and for freight transportation. The company offers a wide ran …
  • Redcape Hotel Group:企業の戦略・SWOT・財務情報
    Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report Summary Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Golden Grain Energy, LLC:企業の戦略的SWOT分析
    Golden Grain Energy, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • CardioComm Solutions Inc (EKG):医療機器:M&Aディール及び事業提携情報
    Summary CardioComm Solutions Inc (CardioComm) is a medical technology company that offers software solutions for information management systems in cardiovascular medicine and telemedicine. The company offers software engineering of computer based electrocardiogram management and reporting software. …
  • Oramed Pharmaceuticals Inc (ORMP):企業の財務・戦略的SWOT分析
    Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Superior Energy Services Inc (SPN):企業の財務・戦略的SWOT分析
    Superior Energy Services Inc (SPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Tele2 AB (TEL2 B):企業の財務・戦略的SWOT分析
    Tele2 AB (TEL2 B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Terumo Cardiovascular Systems Corporation:医療機器:M&Aディール及び事業提携情報
    Summary Terumo Cardiovascular Systems Corporation (TCSC), a subsidiary of Terumo Corporation, is a provider of medical equipment and devices for cardiac and vascular surgeries. It produces hardware products including heart-lung machines and intra-operative monitoring systems for cardiac surgeries. I …
  • Silver Lake Resources Limited:企業の戦略・SWOT・財務情報
    Silver Lake Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Silver Lake Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Karyopharm Therapeutics Inc (KPTI):製薬・医療:M&Aディール及び事業提携情報
    Summary Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclea …
  • CITIC Securities Company Limited:戦略・SWOT・企業財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Fomento de Construcciones y Contratas S.A.:企業の戦略・SWOT・財務分析
    Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report Summary Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Jack Henry & Associates, Inc.:戦略・SWOT・企業財務分析
    Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Erin Energy Corp (ERN):企業の財務・戦略的SWOT分析
    Summary Erin Energy Corp (Erin Energy), formerly CAMAC Energy Inc, a subsidiary of CAMAC Energy Holdings Ltd, is an oil and gas company that develops and produces oil and gas assets. The company's portfolio includes seven licenses in four countries and covers an area of approximately 19,000 sq km of …
  • Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Avingtrans Plc (AVG):企業の財務・戦略的SWOT分析
    Avingtrans Plc (AVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Atlantic Power Corporation:発電所・企業SWOT分析
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Kangwon Land Inc.:企業の戦略・SWOT・財務分析
    Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report Summary Kangwon Land Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • TClarke Plc (CTO):企業の財務・戦略的SWOT分析
    TClarke Plc (CTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆